4 results
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
This study aims to evaluate IDRX-42 administered to participants with metastatic and/or surgically unresectable GIST.
To determine the safety and feasibility of fluorescence imaging of the eye vascularization with the fluorescent tracer bevacizumab-800CW for identification of neovascular Age-related Macular Degeneration (AMD) with scanning laser angiography.
The primary objective of this pilot intervention study is to gain insight into vedolizumab distribution and to identify vedolizumab target cells in the inflamed gut, by performing in- and ex-vivo imaging using a tracer consisting of fluorescently…